CD44 expression and MMP-2 secretion by mouse glioma cells: effect of interferon and anti-CD44 antibody.

Anticancer Res

Department of Anatomy, H. Lee Moffitt Cancer Center and Research Institute, Neuro-Oncology Program and the Neuroscience Program, University of South Florida, College of Medicine, 12901 Bruce B. Downs Blvd., Tampa, Fl. 33612, USA.

Published: March 2001

We have previously reported that invasiveness of mouse glioma G-26, which expresses CD44 adhesion molecule, was inhibited in vitro following treatment with anti-CD44 antibody or mouse interferon alpha/beta (MuIFN alpha/beta). Here, we evaluated whether the expression of transmembrane CD44 adhesion molecule and/or secretion of extracellular matrix metalloproteinases (MMPs) were affected when glioma cell invasion was inhibited. Flow cytometric evaluation of CD44 adhesion molecule expression in G-26 glioma using anti-CD44 antibody, confirmed that G-26 cells were CD44+. Following 3-day treatment with MuIFN alpha/beta at 8 x 10(2) or 8 x 10(3) IU/ml of glioma cells, the expression of CD44 was not significantly affected as reflected by CD44+ cell number and fluorescence intensity. The pretreatment of glioma cells for 1 day with anti-CD44 antibody resulted in a 30-60% decrease of CD44 expression. This coincided with significantly (p < 0.05) lower cell activity as judged by MTT assay for mitochondrial activity. The zymographic evaluation of MMP activity in the G-26 glioma cell culture showed a high level of the active form of MMP-2. This level of MMP-2 was decreased following 3 day treatment of G-26 glioma cells with either 8 x 10(2) or 8 x 10(3) IU/ml of MuIFN alpha/beta but only the latter concentration produced statistically significant 55% decrease. However, following a 1 day treatment of G-26 glioma cells with anti-CD44 antibody, the level of active MMP-2 form was not significantly affected. These findings indicate that while the inhibitory effect of IFN on glioma invasion was accompanied by a decreased level of the active form of MMP-2 released extracellularly, the expression of the transmembrane CD44 adhesion molecule was not affected. Conversely, anti-CD44 antibody pretreatment of G-26 glioma, which led to the inhibition of glioma invasion, resulted in decreased CD44 expression and lower cell activity but had no effect on the MMP-2.

Download full-text PDF

Source

Publication Analysis

Top Keywords

anti-cd44 antibody
24
glioma cells
20
g-26 glioma
20
cd44 adhesion
16
adhesion molecule
16
cd44 expression
12
glioma
12
muifn alpha/beta
12
level active
12
cd44
8

Similar Publications

Enhancing the efficacy of near-infrared photoimmunotherapy through intratumoural delivery of CD44-targeting antibody-photoabsorber conjugates.

EBioMedicine

January 2025

Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan; Department of Immunopathology, World Premier International Research Center, Initiative, Immunology, Frontier Research Center, Osaka University, Osaka, Japan; Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Osaka, Japan; Center for Infectious Diseases for Education and Research, Osaka University, Osaka, Japan; Japan Agency for Medical Research and Development - Core Research for Evolutional Science and Technology, Osaka University, Osaka, Japan; Center for Advanced Modalities and DDS, Osaka University, Osaka, Japan. Electronic address:

Background: Photoimmunotherapy (PIT) is a potent modality for cancer treatment. The conventional PIT regimen involves the systemic delivery of an antibody-photoabsorber conjugate, followed by a 24-h waiting period to ensure adequate localisation on the target cells. Subsequent exposure to near-infrared (NIR) light selectively damages the target cells.

View Article and Find Full Text PDF

Background/objectives: Photoimmunotherapy (PIT) is an innovative approach for the targeted therapy of cancer. In PIT, photosensitizer dyes are conjugated to tumor-specific antibodies for targeted delivery into cancer cells. Upon irradiation with visible light, the photosensitizer dye is activated and induces cancer-specific cell death.

View Article and Find Full Text PDF

Background/objectives: Acute myeloid leukemia (AML) is an aggressive neoplasm. Although most patients respond to induction therapy, they commonly relapse due to recurrent disease in the bone marrow microenvironment (BMME). So, the disruption of the BMME, releasing tumor cells into the peripheral circulation, has therapeutic potential.

View Article and Find Full Text PDF
Article Synopsis
  • - The TREAT-AD program aims to create reliable tools for testing hypotheses related to Alzheimer's disease, emphasizing the need for validated research antibodies used in experiments involving drug targets.
  • - Researchers assessed several commercial antibodies targeting specific proteins (Moesin, CD44, Midkine, and sFRP-1) using Western blot analysis on brain tissues from a mouse model with Alzheimer's pathology.
  • - The study found significant increases in the expression of these target proteins in the Alzheimer's model compared to control mice, confirming the antibodies' effectiveness for future research on Alzheimer's therapeutics.
View Article and Find Full Text PDF
Article Synopsis
  • CD44 is a glycoprotein linked to kidney inflammation and fibrosis, specifically studied in a mouse model for lupus nephritis (LN) and in human patients with active LN.
  • The research showed that CD44 was absent in healthy kidneys but expressed in kidney cells of LN patients, and treatment with anti-CD44 antibodies improved kidney health in mice by reducing immune cell infiltration and fibrosis markers.
  • Serum CD44 levels increased before clinical symptoms of renal flare in patients, effectively distinguishing those with active LN from healthy individuals and other kidney-related conditions.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!